GICS Sector : Healthcare
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain.Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain.It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia.
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
Scilex Holding Company Announces Closing of Previously Announced Second Tranche Investment in Datavault AI Inc., Completing Its Two-Tranche Equity Financing in Datavault AI Inc.
Nov -26
Datavault AI Announces Closing of the Second Tranche of Scilex Holding Company's Previously Announced Equity Financing
Nov -26
Scilex Holding Company Announces Closing of Exercise of Warrants for $20.3 Million Gross Proceeds
Nov -25
Scilex Holding Company Announces Exercise of Warrants for $20.3 Million Gross Proceeds
Nov -24
Scilex Holding Company Announces Update Regarding Distribution of Dream Bowl 2026 Meme Coin by Datavault AI Inc.
Nov -21
Scilex Holding Company Announces that the Board of Directors of Datavault AI Inc. Has Approved the Distribution of a Dream Bowl 2026 Meme Coin to All Eligible Scilex and Datavault AI Stockholders of Record and Set a Record Date of November 25, 2025
Nov -11
Datavault AI Inc. (NASDAQ: DVLT) Issues Investor Update Highlighting Continued Revenue Growth, Strategic Partnerships, and Global Expansion
Nov -10
Datavault AI Inc. Announces a $10M Worldwide Exclusive License Agreement with Scilex Holding Company for Tokenization and Monetization of Real-World Assets (RWA) in Genomic, DNA Data, Diagnostics, Therapeutics, Genetic, and Drug Information
Nov -04
Scilex Holding Company's Non-Opioid Pain Management Products are driven by increasing demand for alternative pain relief options, growing awareness of opioid risks, and expanding prescription rates among healthcare professionals. Additionally, the company's innovative products, strategic partnerships, and strong marketing efforts contribute to its 8.5% growth rate.
A topical system lidocaine patch for the relief of pain associated with post-herpetic neuralgia (PHN)
A topical foam for the treatment of plaque psoriasis
An oral antibiotic for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI)
A topical foam for the treatment of plaque psoriasis
Scilex Holding Company's products are moderately susceptible to substitutes, as there are alternative treatments available for pain management. However, the company's focus on innovative and non-opioid solutions may mitigate this threat.
Scilex Holding Company's customers, primarily healthcare providers and patients, have limited bargaining power due to the company's specialized products and limited competition in the pain management market.
Scilex Holding Company's suppliers, including contract manufacturers and raw material providers, have moderate bargaining power due to the company's dependence on a few key suppliers. However, the company's strong relationships with suppliers mitigate this risk.
The threat of new entrants in the pain management market is low due to high barriers to entry, including significant research and development costs, regulatory hurdles, and the need for specialized expertise.
The intensity of rivalry in the pain management market is high due to the presence of established players and the high stakes of competition. Scilex Holding Company must differentiate its products and services to maintain a competitive edge.
| Value | |
|---|---|
| Debt Weight | -270.22% |
| Debt Cost | 3.95% |
| Equity Weight | 370.22% |
| Equity Cost | 8.52% |
| WACC | 20.86% |
| Leverage | -72.99% |
Value: 6.2
Growth: 7.1
Quality: 5.4
Yield: 0.0
Momentum: 10.0
Volatility: 2.7
1-Year Total Return ->
Value: 8.4
Growth: 4.0
Quality: 5.2
Yield: 0.0
Momentum: 1.5
Volatility: 4.0
1-Year Total Return ->
Value: 8.3
Growth: 6.3
Quality: 5.6
Yield: 0.0
Momentum: 2.0
Volatility: 0.3
1-Year Total Return ->
Value: 8.1
Growth: 1.3
Quality: 2.8
Yield: 0.0
Momentum: 6.5
Volatility: 3.0
1-Year Total Return ->
Value: 7.7
Growth: 1.6
Quality: 4.6
Yield: 0.0
Momentum: 0.0
Volatility: 2.3
1-Year Total Return ->
Value: 9.4
Growth: 0.9
Quality: 4.3
Yield: 0.0
Momentum: 1.0
Volatility: 0.0
1-Year Total Return ->